Study Finds CAR-T Therapy Does Not Increase Risk of Secondary Cancer

New research suggests that CAR-T therapies are as safe as standard treatments regarding the development of second primary malignancies.

Researchers at Memorial Sloan Kettering Cancer Center reviewed data from over 5,500 patients treated with CAR-T therapy.
The study found no significant difference in the rates of secondary cancers between CAR-T and other standard treatments.
Patients who had undergone three or more prior therapies before CAR-T were at higher risk for secondary cancers.
The FDA's previous warning about CAR-T therapy increasing the risk of T-cell cancers may need reconsideration.
Most secondary cancers observed were not T-cell specific, and only one case showed a genetic link to CAR-T therapy.